Does New Jersey Medicaid
Cover Cabenuva?
Cabenuva (Cabotegravir/Rilpivirine) coverage, costs, and how to get it in New Jersey.
Coverage Status
Cabenuva coverage details for New Jersey residents.
PrEP is covered at $0 cost under ACA preventive services. The Ready, Set, PrEP program provides free PrEP for the uninsured.
How to Get Cabenuva Covered
Steps to get Cabenuva covered by your insurance in New Jersey.
Talk to your doctor
Ask your doctor to prescribe Cabenuva and confirm it's appropriate for your condition.
Fill your prescription
Take your prescription to any in-network pharmacy. New Jersey Medicaid should cover it.
Check patient assistance
If coverage is denied, check ViiV Healthcare's patient assistance program for free or reduced-cost options.
Appeal if needed
You can appeal a coverage denial through New Jersey Medicaid. Your doctor can provide supporting documentation.
Need help affording Cabenuva?
Answer 9 questions. See every program you're eligible for. Free.
Cabenuva Side Effects
Common and serious side effects to discuss with your doctor.
โก Common Side Effects
- Injection site reactionscommon
- Fevercommon
- Fatiguecommon
- Headachecommon
โ ๏ธ Serious Side Effects
- Liver problemsrare
Seek immediate medical attention if you experience any serious side effects.
Frequently Asked Questions
Does New Jersey Medicaid cover Cabenuva?
New Jersey Medicaid covered Cabenuva. No prior authorization is needed. PrEP is covered at $0 cost under ACA preventive services. The Ready, Set, PrEP program provides free PrEP for the uninsured.
How much does Cabenuva cost in New Jersey?
Without insurance, Cabenuva costs approximately $5,400/month. With New Jersey Medicaid, your copay may be $0-$0.
How do I get Cabenuva covered in New Jersey?
Contact your New Jersey Medicaid office or insurance provider to check coverage. A prescription from your doctor is typically sufficient.
Get Your Free Benefits Report
Enter your email to receive a personalized report of every benefit program you may qualify for.
No spam. Unsubscribe anytime.